Skip to main content
. 2014 Nov 24;25(12):2123–2128. doi: 10.1021/bc500499h

Figure 3.

Figure 3

(A) Properties of site-specifically and traditionally labeled hybrid PET/OI immunoconjugates. PET (B) and fluorescence (C) images for 89Zr-DFO-sshuA33-Dye680 (top) and 89Zr-DFO-nshuA33-Dye680 (bottom) in mice bearing subcutaneous SW1222 xenografts. Mice were administered 89Zr-DFO-sshuA33-Dye680 or 89Zr-DFO-nshuA33-Dye680 [180–200 μCi (72–80 μg) in 200 μL 0.9% sterile saline] via lateral tail vein injection (t = 0) and imaged 24, 48, 72, 96, and 120 h postinjection. White arrows delineate the xenografts.